Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2

References

• Kettle JG, Åstrand A, Catley M, et al. Inhibitors of JAK-family kinases: an update on the patent literature 2013–2015, part 1. Expert Opin Ther Pat. 2016. doi:10.1080/13543776.2017.1252753.
   Google Scholar
• Durham AL, Caramori G, Chung KF, et al. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res. 2016;167:192–203.
   PubMed Web of Science ®Google Scholar
• Lloyd CM, Saglani S. Epithelial cytokines and pulmonary allergic inflammation. Curr Opin Immunol. 2015;34:52–58.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 Apr 26. doi:10.1016/S0140-6736(16)30307-5. [Epub ahead of print].
   Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–1098.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–756.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692–701.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2:879–890.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016 May 10. doi:10.1016/S2213-2600(16)30031-5. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–2110.
   PubMed Web of Science ®Google Scholar
• Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130:93–100.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328.
   PubMed Web of Science ®Google Scholar
• Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105:1063–1070.
   PubMed Web of Science ®Google Scholar
• Pazdrak K, Stafford S, Alam R. The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils. J Immunol. 1995;155:397–402.
   PubMed Web of Science ®Google Scholar
• Zhong J, Sharma J, Raju R, et al. TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. Database (Oxford). 2014 Feb 25.
   PubMed Web of Science ®Google Scholar
• Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8:1281–1290.
   PubMed Web of Science ®Google Scholar
• Dalby R, Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Deliv Rev. 2003;55:779–791.
   PubMed Web of Science ®Google Scholar
• Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201:937–947.
   PubMed Web of Science ®Google Scholar
• Forbes RL, Gibson PG, Murphy VE, et al. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma. Thorax. 2012;67:209–214.
   PubMed Web of Science ®Google Scholar
• Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12:1023–1026.
   PubMed Web of Science ®Google Scholar
• Raundhal M, Morse C, Khare A, et al. High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest. 2015;125:3037–3050.
   PubMed Web of Science ®Google Scholar
• Chambers ES, Nanzer AM, Pfeffer PE, et al. Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: potential benefits of calcitriol. J Allergy Clin Immunol. 2015;136:628–637.
   PubMed Web of Science ®Google Scholar
• Sykes A, Macintyre J, Edwards MR, et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax. 2014;69:240–246.
   PubMed Web of Science ®Google Scholar
• Kudlacz E, Conklyn M, Andresen C, et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol. 2008;582:154–161.
   PubMed Web of Science ®Google Scholar
• Wiegman CH, Russell KE, Seiffert J, et al. The selective pan-Janus kinase (JAK) inhibitor VR588 demonstrates potent anti-inflammatory activity in a murine chronic house dust mite (HDM) model of asthma. C34. New Basic Sci Asthma Aller Inflam I. 2015 May 1;185:A6435–A6435.
   Google Scholar
• Ashino S, Takeda K, Pine PR, et al. Janus kinase (JAK) 3 inhibitor, R256, attenuates allergen-induced airway hyperresponsiveness and airway inflammation in mice. B33. Asthma Ther. 2012;1:A2766–A2766.
   Google Scholar
• Montes A, Perez-Pampin E, Navarro-Sarabia F, et al. Rhematoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study. Arthritis Res Ther. 2015;17:63.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Ann Rheum Dis. 2013;72:ii111–ii115.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Eloranta M-L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013;25:248–253.
   PubMed Web of Science ®Google Scholar
• Pollard KM, Cauvi DM, Toomey CB, et al. Interferon-γ and systemic autoimmunity. Discov Med. 2013;16:123–131.
   PubMed Web of Science ®Google Scholar
• Thoma G, Drückes P, Zerwes H-G. Selective inhibitors of the Janus kinase Jak3 – are they effective? Bioorg Med Chem Lett. 2014;24:4617–4621.
   PubMed Web of Science ®Google Scholar
• Haan C, Rolvering C, Raulf F, et al. JAK1 has a dominant role over JAK3 in signal transduction through gc-containing cytokine receptors. Chem Biol. 2011;18:314–323.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.
   PubMed Web of Science ®Google Scholar
• Jiangsu Kefeiping Medicine Co Ltd. 4-Substituted pyrrolo[2,3-d]pyrimidine compound and use thereof. WO2015110092; 2015
   Google Scholar
• Jiangsu Hengrui Medicine Co Ltd. Shanghai Hengrui Pharmaceutical Co Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof. WO2013091539. 2013.
   Google Scholar
• Ligand Pharmaceuticals Inc. Janus kinase inhibitor compounds and methods. WO2013025628. 2012.
   Google Scholar
• Merck Sharp & Dohme Corp. Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors. WO2014146493. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp. N-(2-Cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors. WO2014146492. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as Janus kinase inhibitors. WO2013040863. 2013.
   Google Scholar
• Merck Sharp & Dohme Corp. Pyrrolopyrimidines as Janus kinase inhibitors. WO2013085802. 2013.
   Google Scholar
• Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors. WO2013052355. 2013.
   Google Scholar
• Nerviano Medical Sciences Srl. Substituted pyrroles active as kinases inhibitors. WO2014019908. 2014.
   Google Scholar
• Nerviano Medical Sciences Srl. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors. WO2013014039. 2013.
   Google Scholar
• Brasca MG, Gnocchi P, Nesi M, et al. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders. Bioorg Med Chem Lett. 2015;23:2387–2407.
   Web of Science ®Google Scholar
• Nimbus Lakshmi Inc. TYK2 inhibitors and uses thereof. WO2015131080. 2015.
   Google Scholar
• Nissan Chemical Industries Ltd. Tricyclic heterocyclic compounds and JAK inhibitors. WO2013024895. 2012.
   Google Scholar
• Nissan Chemical Industries Ltd. Tricyclic pyrrolopyridine compound, and JAK inhibitor. WO2014123167. 2014.
   Google Scholar
• Novartis Tiergesundheit Ag. New compounds. WO2015144773. 2015.
   Google Scholar
• Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds. WO2011075334. 2011.
   Google Scholar
• F Hoffmann-La Roche AG. Fused tricyclic compounds for use as inhibitors of Janus kinases. WO2013007765. 2012.
   Google Scholar
• Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of Janus-related kinases (JAK). WO2014128591. 2014.
   Google Scholar
• Kaila N, Vazquez M, Unwalla R, et al. Identification of selective JAK1 inhibitors for treatment of autoimmune diseases. MEDI 24, 251st ACS National Meeting, San Diego, CA; 2016 Mar 13–17; Spring Meeting.
   Google Scholar
• Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines. WO2015173683. 2015.
   Google Scholar
• Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides. WO2015083028. 2015.
   Google Scholar
• Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors. WO2012158785. 2012.
   Google Scholar
• Principia Biopharma Inc. Azaindole derivatives as JAK-3 inhibitors. WO2014081732. 2014.
   Google Scholar
• Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol. 2009;2:131–151.
   PubMedGoogle Scholar
• Portola Pharmaceuticals Inc. Bicyclic dihydropyridone kinase inhibitors. WO2014051653. 2014.
   Google Scholar
• Portola Pharmaceuticals Inc. Bicyclic oxa-lactam kinase inhibitors. WO2014051654. 2014.
   Google Scholar
• Portola Pharmaceuticals Inc. Substituted pyrimidinyl kinase inhibitors. WO2014058921. 2014.
   Google Scholar
• Portola Pharmaceuticals Inc. Pyridazine compounds as JAK inhibitors. WO2015123453. 2015.
   Google Scholar
• Principia Biopharma Inc. Azaindole derivatives as JAK-3 inhibitors. WO2014081732. 2014.
   Google Scholar
• F Hoffmann-La Roche AG. Fused tricyclic compounds for use as inhibitors of Janus kinases. WO2013007765. 2013.
   Google Scholar
• F Hoffmann-La Roche AG. Tricyclic heterocyclic compounds, compositions and methods of use thereof as JAK inhibitors. WO2013007768. 2013.
   Google Scholar
• F Hoffmann-La Roche AG. Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors. WO2013030138. 2013.
   Google Scholar
• Padilla F, Bhagirath N, Chen S, et al. Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors. J Med Chem. 2013;56:1677–1692.
   PubMed Web of Science ®Google Scholar
• F Hoffmann-La Roche AG. Genentech Inc. Triazolopyridine compounds, compositions and methods of use thereof. WO2015032286. 2015.
   Google Scholar
• F Hoffmann-La Roche AG. Genentech Inc. Thiazolopyridine compounds, compositions and their use as TYK2 kinase inhibitors. WO2015091584. 2015.
   Google Scholar
• F Hoffmann-La Roche AG. Genentech Inc. Imidazopyridine compounds, compositions and methods of use. WO2013041539. 2012.
   Google Scholar
• F Hoffmann-La Roche AG. Genentech Inc. 5-Chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors. WO2015177326. 2015.
   Google Scholar
• Genentech Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods. WO2011003065. 2011.
   Google Scholar
• F Hoffmann-La Roche AG. Pyrazolo[1,5a]pyrimidine and thieno[3,2b]pyrimidine derivatives as IRAK4 modulators. WO2012007375. 2012.
   Google Scholar
• Sareum Holdings plc. Pharmaceutical compounds. WO2015032423. 2015.
   Google Scholar
• Sareum Ltd. Oxazole tyrosine kinase inhibitors. WO2008139161. 2008.
   Google Scholar
• Sareum Ltd. Pharmaceutical compounds. WO2010055304. 2010.
   Google Scholar
• Shanghai Haihe Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences. WO2015188681. 2015.
   Google Scholar
• China Gateway Technology Development (Shanghai) Co Ltd., Shanghai Yunyi Healthcare Management Co Ltd. Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof. WO2014111037. 2014.
   Google Scholar
• Incyte Corporation. Azetidine and cyclobutane derivatives as JAK inhibitors. WO2009114512. 2009.
   Google Scholar
• Shanghai Yunyi Healthcare Management Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof. WO2013152717. 2013.
   Google Scholar
• Beijing Hanmi Pharmaceutical Co Ltd. Compound inhibiting kinase activities of BTK and/or JAK3. WO2015039612. 2015.
   Google Scholar
• Incyte Corp. JAK1 inhibitors for the treatment of myelodysplastic syndromes. WO2015131031. 2015.
   Google Scholar
• Taiho Pharmaceutical Co Ltd. Azaindole derivative. WO2015119126. 2015.
   Google Scholar
• Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2014157569. 2014.
   Google Scholar
• Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2013125543. 2013.
   Google Scholar
• Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2013180265. 2013.
   Google Scholar
• Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2015016206; 2015.
   Google Scholar
• Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2013146963. 2013.
   Google Scholar
• Tolero Pharmaceuticals Inc. JAK2 and ALK2 inhibitors and methods for their use. WO2014151871. 2014.
   Google Scholar
• Supergen Inc. Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors. WO2008106635. 2008.
   Google Scholar
• Goldberg FW, Ward RA, Powell SJ, et al. Rapid generation of a high quality lead for transforming growth factor-β (TGF-β) type I receptor (ALK5). J Med Chem. 2009;52:7901–7905.
   PubMed Web of Science ®Google Scholar
• Farmer LJ, Ledeboer MW, Hoock T, et al. Discovery of VX-509 (decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases. J Med Chem. 2015;58:7195–7216.
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals Inc. Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor. WO2013070606. 2013.
   Google Scholar
• Vertex Pharmaceuticals Inc. Processes and intermediates for producing azaindoles. WO2013006634. 2013.
   Google Scholar
• Vertex Pharmaceuticals Inc. Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor. WO2014074471. 2014.
   Google Scholar
• Vertex Pharmaceuticals Inc. Pharmaceutical combinations useful for treating rheumatoid arthritis. WO2014201332. 2014.
   Google Scholar
• Vertex Pharmaceuticals Inc. Solid forms of a JAK inhibitor. WO2014110259. 2014.
   Google Scholar
• Vertex Pharmaceuticals Inc. Isotopically enriched azaindoles. WO2015027005. 2015.
   Google Scholar
• YM BioSciences Inc. Phenyl amino pyrimidine bicyclic compounds and uses thereof. WO2014000032. 2014.
   Google Scholar
• DTRM Biopharma Co Ltd. Isoxazole derivative that inhibits activity of Janus kinases (JAKs). WO2014101295. 2014.
   Google Scholar
• Dell CP. Antiproliferative naphthopyrans: biological activity, mechanistic studies and therapeutic potential. Curr Med Chem. 1998;5:179–194.
   PubMed Web of Science ®Google Scholar